Followers | 46 |
Posts | 4429 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
Wednesday, July 30, 2014 9:27:17 AM
Purified Poloxamer 188 (MST-188)
MST-188 (Mast Therapeutics, Inc.) is an investigational agent with potential utility in a
wide range of diseases that are characterized by impaired blood flow. The active ingredient
in MST-188 is a purified form of poloxamer 188. Research has shown that poloxamer 188
lowers blood viscosity, decreases red blood cell aggregation, and decreases friction between red blood cells and vessel walls to increase microvascular blood flow and decrease cell
injury. While it has mostly been studied as a potential treatment for sickle cell disease, it
may also have potential to treat Scleroderma by reducing red blood cell aggregation,
inflammation, and restoring cell membrane integrity. A Phase 3 study of MST-188 in sickle
cell disease is currently underway (May 2014).
Poloxamer 188 is considered safe and is widely used in many over the counter products
such as toothpaste, laxatives, and mouthwash. The FDA approved it more than 50 years
ago as a therapeutic reagent to reduce viscosity of blood before it is used in transfusions.
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM